News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

David Z. I. Cherney, MD, PhD

Articles by David Z. I. Cherney, MD, PhD

Validation of the FINE-CKD Model for Future Health Technology Assessments for Finerenone in Patients With Chronic Kidney Disease And Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Aleksandra Drzewiecka, MSc,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Monika Palarczyk, MSc,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

August 16th 2022

FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

December 8th 2021

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

December 8th 2021

Latest Updated Articles

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
Published: December 8th 2021 | Updated:
FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
Published: December 8th 2021 | Updated:

Trending on AJMC

FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis

HMA Combination Therapy Boosts Survival in Accelerated- or Blast-Phase MPNs

How Medicaid Reforms Could Deepen State Coverage Gaps

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

© 2025 MJH Life Sciences^®

All rights reserved.